Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Pontocerebellar hypoplasia type 1 (PCH1), also known as Norman's disease, is a clinically and genetically heterogeneous group of autosomal recessive disorders with a prenatal onset characterized by diffuse muscular atrophy secondary to pontocerebellar hypoplasia and spinal cord anterior horn cell degeneration resulting in early death.
No HPO annotations are available for this condition.
EXOSC3 pontocerebellar hypoplasia (EXOSC3-PCH) is characterized at birth by skeletal muscle weakness that manifests as hypotonia (sometimes with congenital joint contractures) and poor feeding. In children with prolonged survival, spasticity, dystonia, and seizures become evident. Respiratory insufficiency and swallowing difficulties are common. Intellectual disability is severe. To date, 82 individuals (in 58 families) with EXOSC3-PCH have been described [, , , , , , , , , , , ]. Pregnancy is unremarkable in the majority. Fetal akinesia resulting in prenatal-onset joint contractures and polyhydramnios may occur in 1%-2% of cases . Birth weight and length are normal; birth head circumference varies from normal to small.
Diagnosis of EXOSC3 pontocerebellar hypoplasia (EXOSC3-PCH) should be suspected in children with and characteristic .
Neurologic Findings
Common
Hypotonia (onset is usually at birth, but a later onset is possible)
Signs of neurogenic muscle atrophy, such as muscle atrophy and decreased tendon reflexes
No approved treatments are currently available for pontocerebellar hypoplasia type 1. The disease remains an area of unmet medical need.
Gene therapy approaches for pontocerebellar hypoplasia type 1 have been reported in the published literature.
Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with EXOSC3 pontocerebellar hypoplasia (EXOSC3-PCH), the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 3. Recommended Evaluations Following Initial Diagnosis of EXOSC3 Pontocerebellar Hypoplasia
Table 5.
Recommended Surveillance for Individuals with EXOSC3 Pontocerebellar Hypoplasia
System/Concern | Evaluation | Frequency
| Assess airway pulmonary function secretion management. | Monitoring of respiratory function may be necessary to detect sleep apnea.
Gastrointestinal/
No clinical trials have been registered for pontocerebellar hypoplasia type 1.
159 publications have been identified in PubMed for pontocerebellar hypoplasia type 1. Research spans Review / Meta-Analysis (31%), Basic Science / Preclinical (31%), and Epidemiology / Natural History (13%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 50 | 31% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 6:47 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Source: GeneReviews — "EXOSC3 Pontocerebellar Hypoplasia"
Central motor neuron signs (spasticity, dystonia), especially in individuals with prolonged survival
Lower motor neuron involvement, demonstrated by EMG (abnormal EMG potentials, increased motor unit potentials, fasciculations)
Less common
Joint contractures (can be present at birth or develop later)
Swallowing insufficiency
Ophthalmologic findings of:
Small or pale optic discs indicative of optic atrophy
Nystagmus
Strabismus
Seizures
Source: GeneReviews — "EXOSC3 Pontocerebellar Hypoplasia"
Key disorders to consider in the differential diagnosis of pontocerebellar hypoplasia type 1 (PCH1) include EXOSC8-, SLC25A46-, and VRK1-related PCH1, PCH2/4 (TSEN54-related PCH), spinal muscular atrophy type 1, PCH10, and PCH12 . PCH1. About 50% of individuals with PCH1 have pathogenic variants in EXOSC3 (i.e., EXOSC3-PCH). In children with EXOSC3-PCH, neonatal death, delayed nerve conduction velocities, and congenital respiratory and feeding difficulties occur less frequently than in those without identifiable EXOSC3 pathogenic variants . PCH2/4. Dyskinesias and seizures are common in PCH2, the most common type of PCH. PCH4 is a severe form of PCH2, often with congenital contractures and polyhydramnios. In children with EXOSC3-PCH, central motor findings (together with the typical brain MRI findings of cerebellar or pontocerebellar hypoplasia) may falsely suggest a diagnosis of PCH2. Compared to findings in EXOSC3-PCH, the findings in PCH2 are: • No abnormalities of the spinal cord (whereas in PCH1 anterior horn cells are involved); • Attenuation of the pons on brain MRI (whereas in PCH1 the pons can be unaffected). Table 2. Genes of Interest in the Differential Diagnosis of EXOSC3 Pontocerebellar Hypoplasia
Gene(s) | Phenotype/Disorder | MOI | Brain MRI Findings | Clinical Characteristics |
|---|---|---|---|---|
VRK1 | PCH11,2 | AR | Pontine atrophy may not be present in some individuals. | Lower motor neuron deficits due to loss of anterior horn cells; manifestations of peripheral denervation incl weakness muscle hypotonia from birth; Mixed central (spastic, dystonic) peripheral pareses may be present in those w/prolonged survival; some children w/PCH1 die at an early age.3 |
TSEN54 | TSEN54-PCH (PCH2, 4, 5) | AR | Severe pontocerebellar hypoplasia w/relative sparing of pons; Profound supratentorial atrophy in PCH4 | Generalized clonus, impaired swallowing, dystonia, chorea, progressive microcephaly in PCH2; PCH4 is a severe type of PCH2, w/congenital contractures polyhydramnios. SMN1 |
Spinal muscular atrophy type 1 | AR | Normal | Early-onset (birth-6 mos) disease is characterized by muscle weakness lack of motor development.; Cognitive function is normal.; EMG reveals denervation; muscle biopsy shows grouped atrophy. | — |
CLP1 | PCH10 (OMIM 615803) | AR | Mild cerebellar atrophy/hypoplasia | Very rare disorder characterized by DD, microcephaly, spasticity, axonal motor sensory neuropathy, abnormal muscle tone, seizures, motor neuron degeneration |
COASY | PCH12 (OMIM 618266) | AR | Prenatal-onset microcephaly; hypoplasia of cerebellum, brain stem, spinal cord | Severe prenatal-onset PCH, microcephaly, arthrogryposis w/hypoplasia of spinal cord brain stem, multiple congenital contractures, polyhydramnios, motor neuron degeneration Other disorders to consider ... |
Source: GeneReviews — "EXOSC3 Pontocerebellar Hypoplasia"
Biomarker and diagnostic research for pontocerebellar hypoplasia type 1 has been reported in the published literature.
System/Concern | Evaluation | Comment |
|---|---|---|
Constitutional | Measure length weight. | See Gastrointestinal/Feeding if evidence of failure to thrive. Gastrointestinal/ |
Feeding | Gastroenterology / nutrition / feeding team eval | Assess swallowing feeding to determine safety of oral vs gastrostomy feeding. |
Respiratory | Assess airway pulmonary function secretion management. | Consult pulmonologist. |
Neurologic | Eval by pediatric neurologist | Assess for:; Evidence of severe generalized clonus;; Chorea, spasticity;; Seizures (to incl EEG);; Impaired central vision. |
Hearing loss | Eval by audiologist | — |
Vision | Eval by pediatric ophthalmologist | Assess visual acuity.; Fundoscopy to assess optic nerve |
Musculoskeletal | Multidisciplinary neuromuscular clinic assessment by orthopedist, physical medicine, OT/PT | To incl assessment of:; Contractures, clubfoot, kyphoscoliosis; Need for positioning devices |
Palliative care | Refer to palliative care specialist. | When deemed appropriate by family care providers Genetic |
counseling | By genetics professionals1 | To inform affected persons their families re nature, MOI, implications of EXOSC3-PCH to facilitate medical personal decision making Family support/ resources |
Treatment of Manifestations in Individuals with EXOSC3 Pontocerebellar Hypoplasia Manifestation/Concern | Treatment | Considerations/Other |
Seizures | Per standard practice | By neurologist experienced in epilepsy management |
Irritability | None | Often related to chorea (involuntary movements) |
Musculoskeletal | Multidisciplinary neuromuscular clinic physical medicine, OT/PT | Maximize gross motor fine motor skills through PT/OT use of adaptive devices.; Alternative casting/splinting stretching Orthopedics |
Feeding/Dysphagia | Gastroenterology / nutrition / feeding team | Modify food consistency to aspiration risk /or consider NG feeding gastrostomy. |
Speech | Speech/language eval | Consider involving speech therapist OT to improve communication skills. Respiratory |
Neurodevelopmental | Early intervention / individual education program based on needs | See . NG = nasogastric; OT = occupational therapy, PT = physical therapy The following information represents typical management recommendations for individuals with developmental delay / intellectual disability in the United States; standard recommendations may vary from country to country. |
Source: GeneReviews — "EXOSC3 Pontocerebellar Hypoplasia"
View trials for pontocerebellar hypoplasia type 1
|
Aspiration risk nutritional status
Monitor for constipation.
| Annually; more frequently if needed
|
PT/OT eval
Assess for contractures, scoliosis, foot deformities.
Hip/spine x-rays
|
Monitor those w/seizures as clinically indicated.
Monitor for dystonia choreic movements.
| Monitor developmental milestones
Family support
resources | Family needs
OT = occupational therapy, PT = physical therapy
Source: GeneReviews — "EXOSC3 Pontocerebellar Hypoplasia"
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
Laboratory research
50 |
31% |
Disease patterns and progression | 21 | 13% |
Clinical study results | 12 | 8% |
Patient case studies | 10 | 6% |
Testing and diagnosis research | 8 | 5% |
Other research | 4 | 3% |
New treatment approaches | 4 | 3% |
Drobňaková S (2026). [PMID: 42195294](https://pubmed.ncbi.nlm.nih.gov/42195294/). *Life (Basel)*. [Epidemiology / Natural History]
Pedullà G (2026). [PMID: 41722179](https://pubmed.ncbi.nlm.nih.gov/41722179/). *Parkinsonism Relat Disord*. [Case Report / Case Series]
Ness M (2026). [PMID: 41708203](https://pubmed.ncbi.nlm.nih.gov/41708203/). *Advances in clinical chemistry*. [Epidemiology / Natural History]
Banez-Coronel M (2026). [PMID: 41422503](https://pubmed.ncbi.nlm.nih.gov/41422503/). *Cell Rep*. [Basic Science / Preclinical]
Hmeluk NV (2026). [PMID: 41242621](https://pubmed.ncbi.nlm.nih.gov/41242621/). *J Vasc Surg*. [Epidemiology / Natural History]
Hatchett RJ (2026). [PMID: 41656850](https://pubmed.ncbi.nlm.nih.gov/41656850/). *Disaster Med Public Health Prep*. [Review / Meta-Analysis]
Venturini J (2026). [PMID: 41494000](https://pubmed.ncbi.nlm.nih.gov/41494000/). *PLoS Negl Trop Dis*. [Review / Meta-Analysis]
Rivera-Agudelo L (2026). [PMID: 42042355](https://pubmed.ncbi.nlm.nih.gov/42042355/). *J Fungi (Basel)*. [Review / Meta-Analysis]
Zhu B (2026). [PMID: 41512036](https://pubmed.ncbi.nlm.nih.gov/41512036/). *Proc Natl Acad Sci U S A*. [Diagnostic / Biomarker]
Ranum LPW (2026). [PMID: 41707145](https://pubmed.ncbi.nlm.nih.gov/41707145/). *The New England journal of medicine*. [Clinical Trial Publication]